Have a feature idea you'd love to see implemented?
Let us know!
NUVB Nuvation Bio Inc
Price (delayed)
$2.32
Market cap
$578.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.12
Enterprise value
$558.65M
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and
Highlights
The company's quick ratio has shrunk by 76% YoY and by 70% QoQ
NUVB's equity has dropped by 59% year-on-year and by 57% since the previous quarter
Key stats
What are the main financial stats of NUVB
Market
Valuations
Earnings
Shares outstanding
249.25M
Market cap
$578.25M
Enterprise value
$558.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.23
Price to sales (P/S)
395.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
389.3
Revenue
$1.44M
EBIT
-$510.59M
EBITDA
-$510.29M
Free cash flow
-$84.26M
Per share
Balance sheet
Liquidity
EPS
-$2.12
Free cash flow per share
-$0.34
Book value per share
$1.04
Revenue per share
$0.01
TBVPS
$2.42
Total assets
$594.8M
Total liabilities
$62.67M
Debt
$14.68M
Equity
$257.19M
Working capital
$536.08M
Debt to equity
0.06
Current ratio
11.49
Quick ratio
11.3
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-35,559.9%
Gross margin
6.1%
Net margin
-35,590.2%
Operating margin
-37,474.1%
Return on assets
-83%
Return on equity
-98.8%
Return on invested capital
-90.7%
Return on capital employed
-93.9%
Return on sales
-35,581%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NUVB stock price
How has the Nuvation Bio stock price performed over time
Intraday
-3.73%
1 week
-9.73%
1 month
-15.33%
1 year
101.74%
YTD
53.64%
QTD
1.31%
Financial performance
How have Nuvation Bio's revenue and profit performed over time
Revenue
$1.44M
Gross profit
$88,000
Operating income
-$537.75M
Net income
-$510.72M
Gross margin
6.1%
Net margin
-35,590.2%
Growth
What is Nuvation Bio's growth rate over time
Valuation
What is Nuvation Bio stock price valuation
P/E
N/A
P/B
2.23
P/S
395.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
389.3
The stock's price to book (P/B) is 78% more than its last 4 quarters average of 1.3 but 42% less than its 5-year quarterly average of 4.0
NUVB's equity has dropped by 59% year-on-year and by 57% since the previous quarter
Efficiency
How efficient is Nuvation Bio business performance
Dividends
What is NUVB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NUVB.
Financial health
How did Nuvation Bio financials performed over time
The company's quick ratio has shrunk by 76% YoY and by 70% QoQ
The current ratio has shrunk by 76% YoY and by 70% QoQ
Nuvation Bio's debt is 94% lower than its equity
NUVB's equity has dropped by 59% year-on-year and by 57% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.